the Thanks, testing After the XX. the cancer majority half believe do only turn We'll this past two I company mid-August, leading joining Slide and two in in leader. be customers, meeting half the gain both our especially support. truly months, in deeper information a a decision we spent testing. patients the understanding can vast care of I've that sense In where a category community with to in and NeoGenomics and labs provider settings already of our field months the and Bill. where and market are teammates in business. and Since occurs, oncology the see of I to
vast in foundation whom market us having established many community their majority strong and relationships standing a of long oncologists, the with of the have We send and pathologist deep thousands of testing.
in than see is as the proliferation of the our Neo our These care offering. to a customers partner competitive connection a large but still breadth menu NGS with advantage, delivering physicians patients. our deeper with panels, much The test true of even runs their test
that matters deeply Our our patient to customers. committed teammates to our of improving care, commitment are mission and
pharma built all solid offerings medicine that of continuum as and a activity We've way cover through with companies the from discovery commercialization. serve also translation biopharma the foundation to
our we're With of positioned support very the our the informatics phase for journey. decision expansion next in well capabilities, precision and oncology,
believe it and place That on is a our significantly executed elements improving offering. win service. strategy facing simply initiatives. execution. years, the turnaround optimizing us, enhance of we've we doubt improve customer our making expanding have sales product some easier while for do reducing to This I need organization, an to not customer to the need effective includes we said, in and of that time, experience with field had and on those no business standpoint, but there we that From
and and to focus our chosen profitability. I'm we the more people. confident when on start spend productivity manage need growth, and try do to investment move perspective, market all the that financial efficiency increase begin things all improve few volume our to accelerate we ultimately tightly things, need a From growth, to not to our SG&A and increase we'll share, be of to we these labs,
business significantly And days for finally, to focus we the spent to need means which XX work XX on the including XX first we I next the for get we our the the need will business management. increase over strengths revenue going doing, improvement, cycle and that our to the to need where forward. team XX paid that we're we with our strategic learning finalize and areas, days direction
been revenue we time we the both. and In or asked people, short that believe sacrifice can investors lieu of focus I need that we including I've growth to and company, profitability. several on drive growth profits, well teammates Candidly, do with have to and the
we get sustainable go, profitable From building will the target term long growth.
do our efforts drive drive this, efficiency between to we focus innovation bounce and investments to we As and growth. will operational
and opportunities will will not on pursue We to organization ultimately, set execution. we then pursue the which to focus and clear priorities entire of importantly,
and prioritizing movement in Slide Catalyst, for why This and executing X, been execution is program going the which execute become capture has improvements value to a pointed about better are identifying efficiency. moving to annual Project all right our operational with we direction the really driving foundation framework forward. we While will for need
Let Project the accelerate growth experience that improve actions tell Catalyst to profit. were and in part some drive customer of you me about taking
focus been of optimization. lab One areas of has the on key
deployed have neural technology automate Cytogenetics efficiency with deep analysis XX% or We gains. network to DNN over
automation deployed platforms in deliver also the improvements and Fish that lab Molecular have We major throughput. will for
will digital create and pathology excellence. a specimen of time. that testing are flow lab developing NGS scale of workflow, enhance footprint to turnaround also improve We're And improve centers and rationalize solution we our working to economies for achieve
but initiatives these to throughout both in turnaround see taking test begun hold, in already improvement. there's the for per quarter definitely We've time opportunity still are as improvements cost
reimbursement. growth a the priority enhanced management established strategic As in focus we enhanced competitive pillar, cycle QX to test, XXXX. a in Revenue part billing further improve area cycle and be revenue of revenue management top have will per program improve practices,
approximately continuing our and We're We're both validating RNA XXX NGS with and currently MSI, an cover include mix that product improve DNA our panel also both to client will improved and report experience. average CNVs. TMB and genes
to We turnaround expect significantly time this current new assay than have better our panels.
continue to direction QX update will underway these on call have year. as activities we next and then and strategic in the around occur We pillars additional our you initiatives earnings all our they on more
I'm about prospects to personally of XX, to minute spend radar. excited a I very want also Slide on Moving radar. the
to plans of Our detection this just and proprietary talk for to bit assay the want test. commercialize a And MRD reoccurrence. about our
in is Medicare needed we coverage noted release were on cancer. by in for evidence additional October we informed clinical press to MolDx As our radar secure for XXth, an colorectal order
multi initiate As a result launching MolDx, of with in we prong our radar. a decided discussions to approach
will and MolDx work additional collections begin colorectal cancer. we with data for First,
Second, because our session ASCO in published data Journal have cancer. a of of colorectal QX the breast accelerate presented reviewed launch the at including to of we and into the plenary published strength body already of commercial with We Oncology summer. data this breast of study cancer, launch clinical Along Clinical cancer published peer year. decided of next in the for clinical of our radar have during
continue gain early care continue and But adoption, Medicare team why payers Our experience field to work generating to in clinical and from both commercial will secure we our to initial be gain focus and work payers support to private coverage. with to to closely other data. and patients payment our pay organization adopter evidence gather to reimbursement managed will
remain While confident the we disappointed we decision were in the performance. MolDx, assays from in
clinical We generating as secure incredibly and competent cancers But radar previously colorectal did we from reminder, other meaningful clinical expand disclosed least well any a as other calls, our studies as not anticipate we as XXXX. until revenue remain our for to reimbursement these and ability at Medicare in from payers. will research
to we want move about reimagining talk As service business. Slide XX, our I to pharma
our innovation repositioning are improve accelerate We first drive pharma growth. service to and business then profitability and to
have the and more of of too on is and perform, types transition past focused selective business. projects profitability we the of expense the of the about couple it Over is bookings we about heavily years that being capabilities. discipline the This at about
to improve our most projects. partners. sacrifice of deliver to that as capabilities pharma the we need That enhance partnerships we our have As growth to of innovation with revenue need near-term we said, work high value some mix we business
us to work under farmer the we're care for will And the in our ongoing leadership, a presence opportunity precision our community expect the service product and for partners entire to roadmap an and engine the with be innovation increase building our We business shawls that company. in to closely setting. important patient sashes afforded oncology clinical enhance
high patient be in focusing approach will improvement innovation, to only our chosen strategic drive few our in investments we the Importantly, of on projects potential care. that significant have
of will We be profitable pursuing growth. on return with also these investments consistent of mindful strategy the our
that will over both expect on profitability initiatives have growth meaningful revenue these We time. impact and
of in drive reinvest to for choose to some expect do we improvements While these growth future we margin, gains of company. the may
lifting of improvements We forward of the a front we take fourth are in pleased a detailed the But look are and In still us company move we're time. summary, laying we this confident quarter and providing that in year. we heavy our solid we have right acknowledge the next lot earnings to We starting direction. foundation. with plans will progress more and that made the we are to quarter some report that of
